prostate cancer

Is 1.5 the new magic number for PSA screening?A new approach to prostate cancer screening has been proposed by investigators who claim the idea of informed decision-making by primary care physicians is not working when it comes to PSA testing.
New Products: Test launched to improve prostate biopsy decision processOther new products discussed in this article include a surgical training model, devices designed to improve prostate biopsy accuracy, an updated label and more.
Delay from biopsy to RP: Who is at risk of recurrence?The risk of prostate cancer relapse after radical prostatectomy increases with lengthening delay between diagnosis and surgery. The impact, however, is significant only in high-risk patients, and even in those men, there may be a window of up to 12 months during which it may be relatively safe to postpone surgery, reported researchers from Milan, Italy.
There’s something about PSA: Ben Stiller fights the good fightUrologist Henry Rosevear, MD, discusses actor Ben Stiller's recent blog post that credits PSA tests for saving his life after he was diagnosed with prostate cancer and the urologic community's surprising reaction to the article.
Prostate Ca surveillance study has global implicationsA new study revealing 91% of very low-risk and 74% of low-risk prostate cancer patients in Sweden choose active surveillance should be a benchmark for the use of the management strategy in the U.S. and elsewhere in the world, the study’s authors say.
Large prostate Ca study evaluates RP, radiation, monitoringNearly 100% of patients with clinically localized prostate cancer, detected by PSA testing, survive at an average 10 years’ follow-up, regardless of whether they had active monitoring, radical prostatectomy, or radiotherapy, according to new study results.
Four areas of unnecessary senior healthcare
Four areas of unnecessary senior healthcareTwo reports highlight areas of elderly care that healthcare systems and health plans should avoid.
Test predicts PCSM at 10 years post prostatectomyNew research suggests that urologists can use the Decipher genetic test (GenomeDx Biosciences) to improve predictions of death risk from prostate cancer at10 years after prostatectomy.
HIFU results in low morbidity, QoL preservationAnother study suggests that hemiablation with high-intensity focused ultrasound is a promising treatment for unilateral localized prostate cancer.
How cutting carbs may benefit men on hormonal therapyRecent data show that a low-carbohydrate diet may have significant positive effects in men on hormonal therapy for prostate cancer, including metabolic effects. In this interview, study author Stephen J. Freedland, MD, discusses his group’s findings, ongoing research on diet and lifestyle changes in men with prostate cancer, and how he counsels patients.